Biblio

Author [ Keyword(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Anti-Inflammatory Agents, Non-Steroidal
Uchegbu IF, Florence AT.  1996.  Adverse drug events related to dosage forms and delivery systems.. Drug Saf. 14(1):39-67.
Antibiotics, Antineoplastic
Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT.  1996.  The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models.. J Drug Target. 3(5):399-409.
Uchegbu IF, Double JA, Turton JA, Florence AT.  1995.  Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.. Pharm Res. 12(7):1019-24.
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R et al..  2009.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.. Int J Oncol. 34(6):1629-36.
Sludden J, Uchegbu IF, Schätzlein AG.  2000.  The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution.. J Pharm Pharmacol. 52(4):377-82.
Siew A, Le H, Thiovolet M, Gellert P, Schätzlein A, Uchegbu I.  2012.  Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles.. Mol Pharm. 9(1):14-28.
Schätzlein AG, Rutherford C, Corrihons F, Moore BD.  2001.  Phage derived peptides for targeting of doxorubicin conjugates to solid tumours.. J Control Release. 74(1-3):357-62.
Brucoli F, Natoli A, Marimuthu P, Borrello MTeresa, Stapleton P, Gibbons S, Schätzlein A.  2012.  Efficient synthesis and biological evaluation of proximicins A, B and C.. Bioorg Med Chem. 20(6):2019-24.
Antineoplastic Agents
Gunaratnam M, de la Fuente M, Hampel SM, Todd AK, Reszka AP, Schätzlein A, Neidle S.  2011.  Targeting pancreatic cancer with a G-quadruplex ligand.. Bioorg Med Chem. 19(23):7151-7.
Rahman KM, Jackson PJM, James CH, B Basu P, Hartley JA, de la Fuente M, Schätzlein A, Robson M, R Pedley B, Pepper C et al..  2013.  GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models.. J Med Chem. 56(7):2911-35.
Lalatsa A, Schätzlein AG, Mazza M, Le TBich Hang, Uchegbu IF.  2012.  Amphiphilic poly(L-amino acids) - new materials for drug delivery.. J Control Release. 161(2):523-36.
Schätzlein AG.  2006.  Delivering cancer stem cell therapies - a role for nanomedicines? Eur J Cancer. 42(9):1309-15.
Wong PEe, Tetley L, Dufès C, Chooi KWai, Bolton K, Schätzlein AG, Uchegbu IF.  2010.  Polyamine aza-cyclic compounds demonstrate anti-proliferative activity in vitro but fail to control tumour growth in vivo.. J Pharm Sci. 99(11):4642-57.
Eatock MM, Schatzlein A, Kaye SB.  2000.  Tumour vasculature as a target for anticancer therapy.. Cancer Treat Rev. 26(3):191-204.
Cassidy J, Schätzlein AG.  2004.  Tumour-targeted drug and gene delivery: principles and concepts.. Expert Rev Mol Med. 6(19):1-17.
Cruz IN, Zhang Y, de la Fuente M, Schätzlein A, Yang M.  2013.  Functional characterization of heat shock protein 90 targeted compounds.. Anal Biochem. 438(2):107-9.
Dufès C, Muller J-M, Couet W, Olivier J-C, Uchegbu IF, Schätzlein AG.  2004.  Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.. Pharm Res. 21(1):101-7.

Pages